BusinessBiotech and Pharma
Merck Acquires Cidara Therapeutics for Potential Flu Prevention
Merck is set to acquire Cidara Therapeutics in a $9.2 billion deal, gaining access to Cidara's experimental antiviral drug, CD388, aimed at ...
7 months ago
BusinessBiotech and Pharma
Novartis to Acquire Avidity Biosciences for $12 Billion
8 months agoUS
Novartis has announced its plan to acquire Avidity Biosciences for $12 billion in cash, marking a significant move to bolster its neuroscience pipeline and RNA therapeutics capabilities. The deal is expected to close in the first half of 2026, pending customary closing conditions and the spin-off of Avidity’s early-stage cardiology programs.
Key Insights
•
Novartis will acquire Avidity Biosciences for $72 per share in cash, a 46% premium over Avidity's closing price on October 24, 2025.
•
The acquisition strengthens Novartis’ neuroscience franchise with three late-stage programs targeting genetic neuromuscular diseases.
•
Avidity’s Antibody Oligonucleotide Conjugates (AOCs™) platform will advance Novartis’ xRNA strategy, offering targeted RNA delivery to muscle.
•
The deal is projected to increase Novartis’ sales compound annual growth rate (CAGR) from +5% to +6% between 2024 and 2029.
•
Why this matters: The acquisition allows Novartis to tap into innovative RNA therapeutics, potentially leading to breakthroughs in treating debilitating neuromuscular conditions. It also expands Novartis' pipeline with first-in-class therapeutic candidates.
In-Depth Analysis
Novartis’ acquisition of Avidity Biosciences signifies a strategic investment in RNA-based therapies, a relatively new class of medications that alter gene expression to treat or prevent diseases. Avidity specializes in Antibody Oligonucleotide Conjugates (AOCs™), which enable targeted delivery of RNA therapeutics to muscle tissue. This deal aligns with Novartis’ broader strategy of expanding its research and development division, including a $23 billion investment to build out its U.S.-based infrastructure. The acquisition is expected to provide Novartis with potential first-in-class, late-stage disease-modifying therapies in myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD).
FAQs
•
Q: What are Antibody Oligonucleotide Conjugates (AOCs™)?
AOCs are a class of RNA therapeutics developed by Avidity Biosciences that combine monoclonal antibodies with oligonucleotides for targeted delivery to muscle cells.
•
Q: When is the acquisition expected to close?
The deal is expected to close in the first half of 2026, subject to customary closing conditions and the completion of Avidity’s spin-off of its early-stage cardiology programs.
Key Takeaways
•
Novartis is acquiring Avidity Biosciences to enhance its neuroscience pipeline and RNA therapeutics capabilities.
•
The acquisition will provide Novartis access to Avidity’s AOC platform, enabling targeted RNA delivery to muscle tissue.
•
The deal is expected to close in the first half of 2026 and is projected to increase Novartis’ sales growth rate.
Discussion
Do you think this acquisition will lead to significant advancements in the treatment of neuromuscular diseases? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
Related Articles
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer